A 2-hour-old term newborn with meconium-stained amniotic fluid develops severe hypoxemia (SpO₂ 75% on 100% oxygen) and clinical signs of pulmonary hypertension despite surfactant administration and conventional mechanical ventilation. Echocardiography confirms right-to-left shunting across the foramen ovale. Which drug is indicated to reduce pulmonary vascular resistance in this scenario?

Explanation

## Meconium Aspiration Syndrome with Pulmonary Hypertension: Selective Pulmonary Vasodilation ### Clinical Context: MAS-Associated Pulmonary Hypertension **Key Point:** Meconium aspiration triggers severe pulmonary inflammation and hypoxia, leading to reactive pulmonary vasoconstriction and right-to-left shunting through fetal channels (foramen ovale, ductus arteriosus). ### Why Inhaled Nitric Oxide (iNO) Is First-Line | Feature | Inhaled Nitric Oxide | Systemic Vasodilators | |---------|----------------------|----------------------| | **Site of action** | Selective pulmonary vasculature (inhaled → alveolar delivery) | Systemic (pulmonary + systemic) | | **Systemic hypotension** | Minimal (inactivated by Hb) | Common; requires systemic support | | **Efficacy in MAS** | Proven; reduces ECMO need | Limited; risk of systemic collapse | | **Onset** | Rapid (minutes) | Slower; variable response | | **Mechanism** | ↑ cGMP → smooth muscle relaxation in pulmonary vessels | Variable (see below) | ### Mechanism of iNO in MAS 1. **Selective pulmonary vasodilation:** NO diffuses into pulmonary vascular smooth muscle → activates guanylate cyclase → ↑ cGMP → vasodilation 2. **Rapid inactivation:** NO binds hemoglobin in RBCs → converted to nitrate → no systemic effect 3. **Improves V/Q matching:** Dilates vessels in ventilated lung units → reduces right-to-left shunt 4. **Reduces pulmonary hypertension:** Lowers RV afterload → improves RV function ### iNO Dosing & Monitoring - **Starting dose:** 20 ppm (parts per million) - **Weaning:** Gradual reduction as oxygenation improves - **Monitoring:** Methemoglobin levels (target < 5%); NO₂ levels (target < 5 ppm) **High-Yield:** iNO is the ONLY inhaled selective pulmonary vasodilator approved for neonatal use in the US and is guideline-recommended for MAS with refractory hypoxemia and pulmonary hypertension. ### Why Other Options Are Suboptimal **Clinical Pearl:** Systemic vasodilators (sildenafil, milrinone, dobutamine) cause systemic hypotension, which is catastrophic in a hypoxemic newborn with right-to-left shunting. They may worsen oxygenation by dropping systemic pressure below pulmonary artery pressure, increasing shunt fraction. ### Adjunctive Therapies - **High-frequency oscillatory ventilation (HFOV):** Reduces barotrauma; synergistic with iNO - **Milrinone or dobutamine:** Reserved for systemic hypotension *after* iNO is established; used to maintain systemic perfusion - **Sildenafil:** Emerging role in chronic pulmonary hypertension; not first-line in acute MAS - **ECMO:** Rescue therapy if iNO + optimal ventilation fail **Mnemonic:** **iNO** = **i**nhaled **N**itric **O**xide = selective pulmonary vasodilation without systemic collapse. [cite:Nelson Textbook of Pediatrics 21e Ch 102; Goldsmith et al. Assisted Ventilation of the Neonate 6e]